<DOC>
	<DOCNO>NCT01843842</DOCNO>
	<brief_summary>The purpose study : - ass safety liquid dosage form Ergoferon treatment acute upper respiratory tract infection child ; - ass clinical efficiency liquid dosage form Ergoferon treatment acute upper respiratory tract infection child .</brief_summary>
	<brief_title>Clinical Trial Safety Clinical Efficiency Ergoferon Liquid Dosage Form Treatment Acute Upper Respiratory Tract Infections Children</brief_title>
	<detailed_description>The overall duration patient 's participation trial 6 day ( screening/randomization , therapy onset - day 1 ; study therapy period - 5 day ; follow-up period-1 day ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>1 . Patients sex age 3 year 18 year . 2 . Patients consult doctor within 24 hour onset acute respiratory infection ( body temperature le 38.0°C visiting doctor + intensity symptom ≥ 4 score ( presence least 1 general symptom ≥ 2 score 1 nasal/ throat/ chest symptom ≥ 2 score great number symptom intensity≥1 score ) seasonal morbidity . 3 . The possibility start therapy within 24 hour onset first symptoms acute respiratory infection . 4 . Usage contraceptive method sexually active teenager sex trial within 30 day end participation trial . 5 . Availability information sheet ( Informed Consent form ) parents/adopters patient participation clinical trial , Version 2.1 Version 2.2 , sign one parent/adopter patient . For patient 14 year availability information sheet ( Informed Consent form ) participation clinical trial , Version 2.1 Version 2.2 , sign patient one parent/adopter patient . 1 . Suspected bacterial infection presence severe disease require use antibacterial drug ( include sulfanilamide ) . 2 . Suspected initial manifestation diseases symptom similar acute respiratory infection ( infectious disease , influenzalike syndrome onset systemic connective tissue disorder , oncohematology pathology ) . 3 . Medical history primary secondary immune deficiency : ) lymphoid system immunodeficiency ( Tcell /or Bcell immunity chain , immunodeficiency predominant antibody deficiency ) ; b ) phagocyte deficiency ; c ) complement factor deficiency ; ) combine immunodeficiency include AIDS induce HIV infection ; toxic , autoimmune , infectious , radial panleukopenia syndrome ; general lymphocytopenia syndrome ; syndrome lymphocyte polyclonal activation ; postsplenectomia syndrome ; congenital asplenia ; syndrome immune complex pathology associate infectious , allergic autoimmune disease . 4 . Medical history sarcoidosis . 5 . Oncological disease . 6 . Exacebration decompensation chronic disease affect patient 's ability participate clinical trial . 7 . Medical history polyvalent allergy . 8 . Allergy/ intolerance component medication use treatment . 9 . Impaired glucose tolerance , diabetes mellitus . 10 . Hereditary fructose intolerance ( study drug contains maltitol ) . 11 . Intake medicine list section `` Prohibited concomitant treatment '' 1 month prior inclusion trial . 12 . Pregnancy , unwillingness sexually active female patient use contraceptive method study . 13 . Drug addiction , alcohol usage amount 2 unit alcohol per day part patient 's parents/adopters . 14 . Mental disorder patient patient 's parents/adopters . 15 . Patient 's parents/ adopter , investigator 's point view , fail comply observation requirement trial intake regimen investigate medicine . 16 . Participation clinical trial course 3 month prior inclusion trial . 17 . Patient 's parent/adopter relate research personnel investigative site , directly involve trial immediate relative researcher . The immediate relative include husband/wife , parent , child brother ( sister ) , regardless whether natural adopt . 18 . Patient 's parent/adopter work OOO `` NPF `` Materia Medica Holding '' ( i.e . company 's employee , temporary contract worker appoint official responsible carry research ) immediate relative .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>